| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/26/2003 | CN1399572A Methods and compositions using (-) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists |
| 02/26/2003 | CN1399558A Treatment of viral infections |
| 02/26/2003 | CN1399554A Method and compositions for inhibiting adhesion formation |
| 02/26/2003 | CN1399552A Method and composition for treatment of adenoviral ocular infections |
| 02/26/2003 | CN1399550A Use of flupirtine for alleviating pain caused by degenerative joint diseases in dogs and cats |
| 02/26/2003 | CN1399549A Ultrafinel-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same |
| 02/26/2003 | CN1399548A Composition for treatment of external secretion disorders |
| 02/26/2003 | CN1398612A Nano Chinese medicine threewingnut/Tripterygium prepn and its prepn process |
| 02/26/2003 | CN1398582A Local acne treating device |
| 02/25/2003 | US6525196 5HT1 antagonists for antidepressant therapy |
| 02/25/2003 | US6525102 Increasing storage stability of interleukin-2 by incorporating free base form arginine and succinic acid |
| 02/25/2003 | US6525089 Pharmaceutical composition containing decursin |
| 02/25/2003 | US6525087 Use of known agonists of the central cannabinoid receptor CB1 |
| 02/25/2003 | US6525077 Cyanoguanidine prodrugs |
| 02/25/2003 | US6525073 Prevention or treatment of insomnia with a neurokinin-1 receptor antagonist |
| 02/25/2003 | US6525062 Method of treating pain using nalbuphine and opioid antagonists |
| 02/25/2003 | US6525047 Which are growth hormone secretogogues and increase the level of endogenous growth hormone; treating osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair |
| 02/25/2003 | US6525043 Bicyclic or tricyclic ketones, oximes, amine oxides or amines are used as calcium or potassium channel modulators |
| 02/25/2003 | US6524821 Anti-apoptotic compositions comprising the R1 subunit of herpes simplex virus ribonucleotide reductase or its N-terminal portion; and uses thereof |
| 02/25/2003 | US6524819 And their use in the screening for compounds of use in characterization, diagnosis, and treatment of conditions such as Alzheimer's disease, Down syndrome and other forms of dementia |
| 02/25/2003 | US6524813 Novel polynucleotides and polypeptides of the spo0J family derived from Staphylococcus |
| 02/25/2003 | US6524806 Methods of screening for ligands of human hemetopoietin receptor HU-B1.219 |
| 02/25/2003 | US6524805 Cell expressing said receptors contacted with test compound; if induced response is inhibited by tamoxifen, but not by internal estrogen receptor antagonist then test compound is an agonist |
| 02/25/2003 | US6524795 Diagnostics for cardiovascular disorders |
| 02/25/2003 | US6524623 Therapeutic compositions and methods of use thereof |
| 02/25/2003 | US6524616 Compositions and methods for treating or preventing neurodegeneration and cognitive decline and dysfunction associated with alzheimer's disease, aging, other dementia related disorders and estrogen deficiency related conditions |
| 02/25/2003 | US6524610 Nutritional composition made from conventional foods for mixing onsite in a blender and treating patients with hepatic disorders |
| 02/25/2003 | US6524607 Nontoxic, nonglucocorticoid, biocompatible, biodegradable, controlled release material |
| 02/25/2003 | US6524583 Inhibit angiogenesis and induce tumor regression, and have improved safety due to their specificity |
| 02/25/2003 | US6524580 Method for treating thyroid disorders |
| 02/25/2003 | US6524579 Diagnosing, treating or preventing disorders associated with expression of RNABP, cancer, immune disorder, developmental disorders |
| 02/25/2003 | US6524556 Tricyclic compound dispersed in liquefied hydrofluoroalkane propellant; medium-chain fatty acid triglyceride as dispersant |
| 02/21/2003 | CA2398766A1 Treatments for female sexual dysfunction and methods for identifying compounds useful for treating female sexual dysfunction |
| 02/20/2003 | WO2003014745A2 Method for identifying anti-inflammatory drugs |
| 02/20/2003 | WO2003014731A2 The natural ligand for orphan g protein coupled receptor gpr86 and methods of use |
| 02/20/2003 | WO2003014702A2 Uses of mammalian cytokine; related reagents |
| 02/20/2003 | WO2003014391A2 Method for the detection of a polymorphism in cpb2 |
| 02/20/2003 | WO2003014333A1 Use of lysyl oxidase inhibitors for cell culture and tissue engineering |
| 02/20/2003 | WO2003014326A2 Isolation and mobilization of stem cells expressing vegfr-1 |
| 02/20/2003 | WO2003014322A2 Proteins associated with cell growth, differentiation, and death |
| 02/20/2003 | WO2003014321A2 Compositions and methods for modulation of darpp-32 phosphorylation |
| 02/20/2003 | WO2003014309A2 Interleukin-1 receptors in the treatment of diseases |
| 02/20/2003 | WO2003014301A2 Hprp4s as modifiers of the p53 pathway and methods of use |
| 02/20/2003 | WO2003014300A2 TRPS AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
| 02/20/2003 | WO2003014299A2 SPHKs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
| 02/20/2003 | WO2003014159A1 Methods of screening based on the egf receptor crystal structure |
| 02/20/2003 | WO2003014153A2 Cellular virus receptors and methods of use. |
| 02/20/2003 | WO2003014145A2 Peptides that bind to atherosclerotic lesions |
| 02/20/2003 | WO2003014105A1 Bicyclic compound, production and use as hiv inhibitors |
| 02/20/2003 | WO2003013656A2 Non-peptide ccr1 receptor antagonists for the treatment of progressive renal fibrosis |
| 02/20/2003 | WO2003013655A2 Carbonic anhydrase inhibitors |
| 02/20/2003 | WO2003013614A1 Collagen-containing oral preparations, drugs and quasi drugs |
| 02/20/2003 | WO2003013609A1 Sustained-release medicines |
| 02/20/2003 | WO2003013608A1 ORAL PHARMACEUTICAL COMPOSITION CONTAINING A COMBINAITION OF PPARα AND A HMG-COA REDUCTASE INHIBITOR |
| 02/20/2003 | WO2003013603A1 Modulators of p-selectin glycoprotein ligand 1 |
| 02/20/2003 | WO2003013602A1 Inhibitors of her3 activity |
| 02/20/2003 | WO2003013577A2 Use of il-18 inhibitors in hypersensitivity disorders |
| 02/20/2003 | WO2003013576A1 Regulation of the apj receptor for use in the treatment or prophylaxis of cardiac diseases |
| 02/20/2003 | WO2003013575A1 Modulation of leukocyte-endothelial interactions following ischemia |
| 02/20/2003 | WO2003013571A1 Peptidomimetics of biologically active metallopeptides |
| 02/20/2003 | WO2003013566A1 High molecular weight, lipophilic, orally ingestible bioactive agents in formulations having improved bioavailability |
| 02/20/2003 | WO2003013549A2 Formulation containing (lyso-) phosphatidylserine for the prevention and treatment of stress states in warm-blooded animals |
| 02/20/2003 | WO2003013540A1 Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia |
| 02/20/2003 | WO2003013538A1 Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
| 02/20/2003 | WO2003013537A2 Irinotecan for treatment of cancer |
| 02/20/2003 | WO2003013536A2 Methods for treatment of cancer using irinotecan based on ugt1a1 |
| 02/20/2003 | WO2003013535A2 Use of irinotecan for improved treatment of cancer based on mdr1 |
| 02/20/2003 | WO2003013534A2 Methods for the treatment of cancer with irinotecan based on cyp3a5 |
| 02/20/2003 | WO2003013533A2 Methods for improved treatment of cancer with irinotecan based on mrp1 |
| 02/20/2003 | WO2003013525A1 Opioid agonist formulations with releasable and sequestered antagonist |
| 02/20/2003 | WO2003013521A1 Compounds for eliminating and/or relieving anhedonia |
| 02/20/2003 | WO2003013520A1 Pramipexole for the treatment of adhd |
| 02/20/2003 | WO2003013519A1 Pramipexol as an anticonvulsive agent |
| 02/20/2003 | WO2003013517A1 Aminoisoxazole derivatives active as kinase inhibitors |
| 02/20/2003 | WO2003013511A1 Integrin inhibitors for the treatment of eye diseases |
| 02/20/2003 | WO2003013492A1 Combination therapy for the treatment of neurological disorders |
| 02/20/2003 | WO2003013490A1 Nutricional and therapeutical preparations having antioxidant activity |
| 02/20/2003 | WO2003013486A1 The treatment of lipodystrophy |
| 02/20/2003 | WO2003013485A1 Inhibitors of hb-egf (erbb) receptors for treating myeloma |
| 02/20/2003 | WO2003013481A1 The process of manufacturing pharmaceutical composition with increased content of poorly soluble pharmaceutical ingredients |
| 02/20/2003 | WO2003013479A1 Compositions and methods to prevent abuse of opioids |
| 02/20/2003 | WO2003013475A1 Injectable foam and novel pharmaceutical applications thereof |
| 02/20/2003 | WO2003013473A1 Stabilized oral suspension formulation |
| 02/20/2003 | WO2003013438A2 Nutrient therapy for immuno-compromised patients |
| 02/20/2003 | WO2003013434A2 Methods and compositions for treating diseases associated with excesses in ace |
| 02/20/2003 | WO2003013432A2 Methods of use for novel sulfur containing organic nitrate compounds |
| 02/20/2003 | WO2003013424A2 Use of r-nsaid compounds for anti-hiv treatment |
| 02/20/2003 | WO2003013245A1 Polyamines and analogs for protecting cells during cancer chemotherapy and radiotherapy |
| 02/20/2003 | WO2003006001A8 ss-ADRENERGIC BLOCKADE REVERSAL OF CATABOLISM AFTER SEVERE BURN |
| 02/20/2003 | WO2002099138A3 HS2STs AS MODIFIERS OF THE P53 PATHWAY AND METHODS OF USE |
| 02/20/2003 | WO2002096927A3 Ribozyme based treatment of female reproductive diseases |
| 02/20/2003 | WO2002096516A8 Use of compositions comprising cyclooxygenase-2 selective inhibitors in combination with radiation for inhibition or prevention of cardiovascular disease |
| 02/20/2003 | WO2002096422A3 Combination of a dopamine d2-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways |
| 02/20/2003 | WO2002094874A3 Internalisation of virus into cells |
| 02/20/2003 | WO2002088323A3 Gene delivery compounds |
| 02/20/2003 | WO2002085368A3 Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders |
| 02/20/2003 | WO2002080889A3 A combination dosage of a cyclooxygenase (cox) inhibitor, a vitamin d3 including analogues and metabolites thereof and/or calcium for prevention of epithelial cancer |
| 02/20/2003 | WO2002076437A3 Methods for treating neurodegenerative diseases including alzheimer's |
| 02/20/2003 | WO2002076398A3 Improved forms of pharmaceutically active agents and method for manufacture thereof |
| 02/20/2003 | WO2002074246A3 Method and compositions for optimizing blood and tissue stability of camptothecin and other albumin-binding therapeutic compounds |